



The Impact of Liquid Biopsies on Clinical Practice in Oncology

Guest Editors:

Dr. Amber Gonda

Department of Cell Biology and
Physiology, Brigham Young
University, Provo, UT, USA

Dr. Maheswari Senthil

Division of Surgical Oncology,
University of California Irvine,
3800 Chapman Ave, Ste 6400,
Orange, CA 92868, USA

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

Dear Colleagues,

Current modalities of imaging and tissue biopsies, while essential to current tumor monitoring and characterization, have significant weaknesses that “liquid biopsies” seek to address. Liquid biopsies promise a novel approach to detecting tumor presence, growth, and recurrence. While the development of liquid biopsy tools is a very active focus of research, the translation of the work for use in oncology remains an urgent need for improved patient care and the implementation of personalized treatment decision-making. The aim of this Special Issue is to highlight the work that is being carried out to develop liquid biopsies into practical clinical applications. Among other topics, we are seeking original research and review articles that elucidate the successes and weaknesses of the clinical implementation of liquid biopsies, identify biomarkers and analytes of clinically actionable cancer progression, illustrate strategies for the translation of potential liquid biopsy targets into the oncology clinic, or explore the application of liquid biopsy tools for prognostic or therapeutic guidance.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)